Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Dna Script S.A.S.
BioCentury | Oct 18, 2024
Management Tracks
Co-founders Mulvaney, Brennan return to BenevolentAI as CEO Moeller departs
Plus: Sage downsizes and updates from Xaira, DNA Script, Renovaro, Achieve, Adverum and more
BioCentury | Dec 15, 2022
Emerging Company Profile
Ribbon: high-throughput enzymatic assembly of long DNA molecules
Vienna-based Ribbon aims to reduce a bottleneck in the development of biologics
BioCentury | May 11, 2022
Management Tracks
Shea replacing Kim as CEO of Inovio
Plus new chief commercial officer at DNA Script, and updates from Boston Pharma, Quantum SI, Beta, Longeveron and more
BioCentury | Apr 12, 2022
Emerging Company Profile
Ansa debuts with $68M series A for enzymatic DNA synthesis, hold the blocking groups
By using enzyme-cleavable linkers instead of blocking groups, Ansa can generate long, undamaged DNA molecules
BioCentury | Mar 7, 2022
Finance
Aiming to be ‘European anchor’ in expansion rounds, Kurma raises €160M toward growth fund
Seeking to maintain bigger stakes in later rounds, Kurma raises growth fund amid turbulent public markets
BioCentury | Jan 6, 2022
Finance
Jan. 5 Quick Takes: Eventide leads mega-round by Korro
Plus Saliogen raises $115M series B and updates from
BioCentury | May 5, 2021
Finance
Europe’s top venture fund-raisers in 2018-20: Data Byte
At least six European biotechs raised more than $100 million in 2018-20 and are still private, with Oxford Nanopore Technologies Ltd. topping the list at $314.6 million. A further four companies
BioCentury | Sep 13, 2019
Tools & Techniques
Enzymes aim to beat chemistry by creating longer, speedier, cleaner DNA strands
Companies are pushing the limits of DNA synthesis by turning from chemistry to enzymes
BioCentury | Jul 18, 2019
Emerging Company Profile
DNA Script: enzymatic DNA synthesis
How DNA Script plans to help researchers speed R&D with its enzymatic DNA synthesis technology
BioCentury | May 20, 2019
Financial News
May 20 Financial Quick Takes: Schrödinger tops off E round; plus Mabpharm IPO update, DNA Script, ADMA Biologics, Storm
Items per page:
1 - 10 of 11